Alpha memo: resveratrol exercise training cross-context evidence signal

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Confirm and report the exact MAP change in both exercise+placebo and exercise+resveratrol arms from the full text of Gliemann et al. 2013 (J Physiol), and restate the 'blunting' claim with the actual between-group effect size rather than relying on the truncated '45' figure.
2. Add a brief note on allometric scaling (mouse 15 mg/kg/day ≈ ~1.2 mg/kg human equivalent, far below the 250 mg/day used) to make explicit why dose-confounding is a real axis of difference, not just a listed caveat.
3. Soften 'context-dependent split' to 'cross-context divergence' or similar to avoid implying a single mechanism that flips sign; the contrast is better framed as mechanistic protection in one tissue/species vs. functional attenuation in another tissue/species.

Major issues

• Receipt 2's exact MAP change is truncated in the supplied abstract excerpt ('Exercise training led to a 45') and the manuscript acknowledges the comparator figure is omitted. The memo's central contrast rests on the direction/magnitude of the cardiovascular effect, so this truncation materially weakens source-grounding for the 'blunting' claim.

Minor issues

• The 'Why this is surprising' framing slightly overstates the asymmetry: Receipt 1 is a mechanistic mouse tissue study, while Receipt 2 is a small functional human RCT — these were never designed to test the same hypothesis, so calling it a 'context-dependent split' over-anchors on a genuine but expected cross-species/tissue difference.
• Receipt 1 (2023) postdates Receipt 2 (2013), so the temporal ordering in the caveats ('2013 paper is the later-published human clinical update relative to earlier resveratrol mechanistic work') reads as a minor inconsistency with the stated publication years.
• Dose comparison (15 mg/kg/day in mice vs. 250 mg/day in humans) is flagged as non-equivalent but no allometric scaling estimate is provided; a rough human-equivalent dose range would sharpen the falsifiability of the contrast.

Reviewer note

Bounded alpha-memo on a genuine cross-context contrast between resveratrol as intestinal protectant in mice (Nrf2/FTH1/GPX4, 2023) and resveratrol as cardiovascular training-response attenuator in aged men (Gliemann 2013). The receipts match the title's anchor compounds, populations, and endpoints. Limitations and falsifiers are unusually thorough and the memo is appropriately conservative about clinical/dosing recommendations. The main weakness is that the central quantitative claim (magnitude of MAP blunting) cannot be verified from the supplied bundle because the abstract excerpt is truncated mid-sentence at 'Exercise training led to a 45'. This drops source_grounding and claim_evidence_alignment just below 4. Bounded revisions — confirming the exact MAP values and softening the framing — would bring this to accept. Not a reject: the memo is honest about its bounds, cites real sources, and does not overclaim clinical or policy recommendations.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak_failed_conservative

Prompt: reviewer-v11-research-synthesis